

## Answering reviewers

### Reviewer 03647159

Clarification of how outcome of adjuvant chemotherapy should be analyzed is specified in greater detail at page 11, lines 8-11.

### Reviewer 02510721

Addresses mostly the same question, and the perspective of this reviewer has been considered and built into the revised text. However, the lower three lines in this comment suggest that this reviewer did not catch an important point in the manuscript: Site of tumor origin and subtype differentiation should not be mixed concepts. The suggestion of “a clear and detailed distinction of each neoplastic lesion” cannot and should not be met.

### Reviewer 02543991

The request of more about the future direction for improving clinical outcome in pancreatic cancer, is met by the addition of a new section, page 12, lines 8-14.